In the assessment and management of lung adenocarcinoma, activation of the driver pathway should be assessed not only on the basis of individual hotspot mutations (e.g., EGFR L858R), but also on the basis of multiple mRNA expression profiles to predict the role of the EGFR pathway in lung cancer cells, and a study by EGFR-LEONG et al. showed the single-region whole-genome sequencing of 20 lung cancer cases. This evidence concerns the gene EGFR and lung cancer.